November 14, 2013

Clinical testing will commence in Nuclea’s CLIA laboratory in the first quarter of 2014

Pittsfield, MA—Nuclea Biotechnologies today announced they had received a new patent for one of its immunohistochemistry (IHC) assays. U.S. Patent No. 8,580,926 B2, which was issued on November 12, 2013, is for an IHC assay used to determine if a patient diagnosed with colorectal cancer (CRC) will respond to treatment with irinotecan (CAMPTOSAR®).

Irinotecan (CAMPTOSAR®) is a first-line chemotherapeutic agent indicated for first-line therapy for patients with metastatic carcinoma of the colon or rectum. It is used in combination with 5-fluorouracil and leucovorin. The drug is a topoisomerase inhibitor and is also indicated for patients with metastatic CRC whose disease has recurred or progressed following the initial fluorouracil-based therapy.  Nuclea’s test provides doctors with a valuable tool to identify those patients whose tumor is likely to respond to the drug. This is especially important as in certain populations irinotecan (CAMPTOSAR®) may be toxic.

"For the population it works for, irinotecan (CAMPTOSAR®) is a very effective drug," said Patrick J. Muraca, President and CEO of Nuclea. "This test will determine which patients with CRC will respond well to the treatment. Greater knowledge in advance of treatment allows doctors to make more informed decisions about patient care. We look forward to beginning the clinical testing of this high value test in our lab early next year."

Nuclea Biotechnologies, Inc. -- is headquartered in Pittsfield, Massachusetts with additional operations in Worcester and Cambridge, Massachusetts. Nuclea has developed and is commercializing unique diagnostic tests for colon, breast, leukemia, lung and prostate cancer. Nuclea also performs research leading to novel molecular oncology companion diagnostics for the pharmaceutical and biotechnology industries.


Membership Deliverables

MassBio Membership gives you:

Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members. 

Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.

MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.

Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.

Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.

Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!

Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.